{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:16:26Z","timestamp":1787030186995,"version":"build-2736575974"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The protection provided by smallpox vaccines when used after exposure to Orthopoxviruses is poorly understood. Postexposu re administration of 1st generation smallpox vaccines was effective during eradication. However, historical epidemiological reports and animal studies on postexposure vaccination are difficult to extrapolate to today\u2019s populations, and 2nd and 3rd generation vaccines, developed after eradication, have not been widely tested in postexposure vaccination scenarios. In addition to concerns about preparedness for a potential malevolent reintroduction of variola virus, humans are becoming increasingly exposed to naturally occurring zoonotic orthopoxviruses and, following these exposures, disease severity is worse in individuals who never received smallpox vaccination. This study investigated whether postexposure vaccination of prairie dogs with 2nd and 3rd generation smallpox vaccines was protective against monkeypox disease in four exposure scenarios. We infected animals with monkeypox virus at doses of 104 pfu (2\u00d7 LD50) or 106 pfu (170\u00d7 LD50) and vaccinated the animals with IMVAMUNE\u00ae or ACAM2000\u00ae either 1 or 3 days after challenge. Our results indicated that postexposure vaccination protected the animals to some degree from the 2\u00d7 LD50, but not the 170\u00d7 LD5 challenge. In the 2\u00d7 LD50 challenge, we also observed that administration of vaccine at 1 day was more effective than administration at 3 days postexposure for IMVAMUNE\u00ae, but ACAM2000\u00ae was similarly effective at either postexposure vaccination time-point. The effects of postexposure vaccination and correlations with survival of total and neutralizing antibody responses, protein targets, take formation, weight loss, rash burden, and viral DNA are also presented.<\/jats:p>","DOI":"10.3390\/vaccines8030396","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T10:59:38Z","timestamp":1595242778000},"page":"396","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["IMVAMUNE\u00ae and ACAM2000\u00ae Provide Different Protection against Disease When Administered Postexposure in an Intranasal Monkeypox Challenge Prairie Dog Model"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-4730","authenticated-orcid":false,"given":"M. Shannon","family":"Keckler","sequence":"first","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"},{"name":"Clinical and Environmental Microbiology Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna S","family":"Salzer","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"},{"name":"Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Patel","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"},{"name":"Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Townsend","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori J","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Doty","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia F","family":"Gallardo-Romero","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayampalli S","family":"Satheshkumar","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin S","family":"Carroll","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"},{"name":"Office of the Director, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Karem","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"},{"name":"Office of the Director, Center for Global Health, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-0677","authenticated-orcid":false,"given":"Inger K","family":"Damon","sequence":"additional","affiliation":[{"name":"Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"ref_1","unstructured":"WHO (1980). Declaration of Global Eradication of Smallpox, Thirty-Third World Health Assembly."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcpa.2017.12.003","article-title":"Atypical Cowpox Virus Infection in a Series of Cats","volume":"158","author":"Jungwirth","year":"2018","journal-title":"J. Comp. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.15585\/mmwr.mm6710a5","article-title":"Emergence of Monkeypox\u2014West and Central Africa, 1970\u20132017","volume":"67","author":"Durski","year":"2018","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2406.180017","article-title":"Reemergence of Human Monkeypox in Nigeria, 2017","volume":"24","author":"Aruna","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3201\/eid2401.170430","article-title":"Ocular Vaccinia Infection in Dairy Worker, Brazil","volume":"24","author":"Lima","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa1407647","article-title":"Human infection with a zoonotic orthopoxvirus in the country of Georgia","volume":"372","author":"Vora","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Noyce, R.S., Lederman, S., and Evans, D.H. (2018). Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0188453"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tim.2011.12.001","article-title":"Outbreaks of human monkeypox after cessation of smallpox vaccination","volume":"20","author":"Reynolds","year":"2012","journal-title":"Trends Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0022-3476(72)80199-9","article-title":"Smallpox vaccination in the United States: The end of an era","volume":"81","author":"Karzon","year":"1972","journal-title":"J. Pediatrics"},{"key":"ref_10","unstructured":"Fenner, F. (1988). Smallpox and Its Eradication, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/phn.12291","article-title":"Estimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine","volume":"34","author":"Carlin","year":"2017","journal-title":"Public Health Nurs."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4161\/hv.4.2.5217","article-title":"Self-reported adverse health events following smallpox vaccination in a large prospective study of US military service members","volume":"4","author":"Wells","year":"2008","journal-title":"Hum. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/phn.12208","article-title":"Vaccination-Related Side Effects, Humoral Immunity, and Adverse Events during the Civilian Smallpox Vaccination Campaign, Arkansas, 2003","volume":"33","author":"Haselow","year":"2016","journal-title":"Public Health Nurs."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses-Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","unstructured":"FDA (2018, July 23). JYNNEOS. Smallpox and Monkeypox vaccine, Non-replicating-Approval, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/jynneos."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/hs.2014.0066","article-title":"US disaster planners\u2019 attitudes regarding preevent vaccine for first responders and point-of-dispensing workers","volume":"13","author":"Rebmann","year":"2015","journal-title":"Health Secur."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1590\/0074-02760150215","article-title":"Evaluating anti-Orthopoxvirus antibodies in individuals from Brazilian rural areas prior to the bovine vaccinia era","volume":"110","author":"Mota","year":"2015","journal-title":"Mem. do Inst. Oswaldo Cruz"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Eder, I., Vollmar, P., Pfeffer, M., Naether, P., Rodloff, A.C., and Meyer, H. (2017). Two Distinct Clinical Courses of Human Cowpox, Germany, 2015. Viruses, 9.","DOI":"10.3390\/v9120375"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1016\/j.vaccine.2013.08.039","article-title":"The effects of post-exposure smallpox vaccination on clinical disease presentation: Addressing the data gaps between historical epidemiology and modern surrogate model data","volume":"31","author":"Keckler","year":"2013","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0141076815605211","article-title":"Lessons from a modern review of the smallpox eradication files","volume":"108","author":"Metzger","year":"2015","journal-title":"J. R. Soc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1128\/CVI.00056-12","article-title":"Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines","volume":"19","author":"Hughes","year":"2012","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/tbed.12364","article-title":"Using the Ground Squirrel (Marmota bobak) as an Animal Model to Assess Monkeypox Drug Efficacy","volume":"64","author":"Sergeev","year":"2017","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Garver, J., Weber, L., Vela, E.M., Anderson, M., Warren, R., Merchlinsky, M., Houchens, C., and Rogers, J.V. (2016). Ectromelia Virus Disease Characterization in the BALB\/c Mouse: A Surrogate Model for Assessment of Smallpox Medical Countermeasures. Viruses, 8.","DOI":"10.3390\/v8070203"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Falendysz, E.A., Lopera, J.G., Lorenzsonn, F., Salzer, J.S., Hutson, C.L., Doty, J., Gallardo-Romero, N., Carroll, D.S., Osorio, J.E., and Rocke, T.E. (2015). Further Assessment of Monkeypox Virus Infection in Gambian Pouched Rats (Cricetomys gambianus) Using In Vivo Bioluminescent Imaging. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0004130"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.00621-10","article-title":"Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models","volume":"84","author":"Americo","year":"2010","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mucker, E.M., Chapman, J., Huzella, L.M., Huggins, J.W., Shamblin, J., Robinson, C.G., and Hensley, L.E. (2015). Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131742"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-61779-876-4_11","article-title":"Mousepox, a small animal model of smallpox","volume":"890","author":"Esteban","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1099\/vir.0.026237-0","article-title":"Rabbitpox: A model of airborne transmission of smallpox","volume":"92","author":"Nalca","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.virol.2011.07.013","article-title":"Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox","volume":"418","author":"Johnson","year":"2011","journal-title":"Virology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1099\/vir.0.005108-0","article-title":"A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus","volume":"90","author":"Hutson","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/JVI.02012-09","article-title":"A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus","volume":"84","author":"Stabenow","year":"2010","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3390\/v2091918","article-title":"Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics","volume":"2","author":"Parker","year":"2010","journal-title":"Viruses"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kramski, M., Matz-Rensing, K., Stahl-Hennig, C., Kaup, F.J., Nitsche, A., Pauli, G., and Ellerbrok, H. (2010). A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010412"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1177\/0300985810378649","article-title":"Animal models of orthopoxvirus infection","volume":"47","author":"Chapman","year":"2010","journal-title":"Vet. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/v2122763","article-title":"Monkeypox virus infections in small animal models for evaluation of anti-poxvirus agents","volume":"2","author":"Hutson","year":"2010","journal-title":"Viruses"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3201\/eid1104.040907","article-title":"Experimental infection of prairie dogs with monkeypox virus","volume":"11","author":"Xiao","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3201\/eid1003.030878","article-title":"Monkeypox transmission and pathogenesis in prairie dogs","volume":"10","author":"Guarner","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7683","DOI":"10.1128\/JVI.02174-10","article-title":"Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges","volume":"85","author":"Keckler","year":"2011","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.02173-10","article-title":"Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus","volume":"85","author":"Smith","year":"2011","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7883\/yoken.JJID.2016.417","article-title":"A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox","volume":"70","author":"Iizuka","year":"2017","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1128\/JVI.03481-12","article-title":"Assessment of the protective effect of IMVAMUNE(R) and ACAM2000(R) vaccines against aerosolised Monkeypox virus in cynomolgus macaques","volume":"84","author":"Hatch","year":"2013","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"970424","DOI":"10.1155\/2011\/970424","article-title":"Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: Vaccinia Tiantan strain","volume":"2011","author":"Lu","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.vaccine.2009.12.038","article-title":"One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Golden, J.W., Josleyn, M., Mucker, E.M., Hung, C.F., Loudon, P.T., Wu, T.C., and Hooper, J.W. (2012). Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042353"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.vaccine.2009.01.010","article-title":"Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys","volume":"27","author":"Grandpre","year":"2009","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lauterbach, H., Kassub, R., Patzold, J., Korner, J., Bruckel, M., Verschoor, A., Chaplin, P., Suter, M., and Hochrein, H. (2010). Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009659"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI33940","article-title":"Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection","volume":"118","author":"Samuelsson","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1128\/JVI.00945-14","article-title":"Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara","volume":"88","author":"Volz","year":"2014","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Melamed, S., Israely, T., and Paran, N. (2018). Challenges and Achievements in Prevention and Treatment of Smallpox. Vaccines, 6.","DOI":"10.3390\/vaccines6010008"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/595565","article-title":"Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox","volume":"199","author":"Paran","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4161\/hv.10295","article-title":"Smallpox vaccines: New formulations and revised strategies for vaccination","volume":"5","author":"Paran","year":"2009","journal-title":"Hum. Vaccin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1128\/JVI.03029-14","article-title":"Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus","volume":"89","author":"Tree","year":"2015","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2015.02.044","article-title":"Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease","volume":"481","author":"Johnson","year":"2015","journal-title":"Virology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"965710","DOI":"10.1155\/2015\/965710","article-title":"Comparison of Monkeypox Virus Clade Kinetics and Pathology within the Prairie Dog Animal Model Using a Serial Sacrifice Study Design","volume":"2015","author":"Hutson","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virol.2013.11.017","article-title":"Susceptibility of the wild-derived inbred CAST\/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging","volume":"449","author":"Americo","year":"2014","journal-title":"Virology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/JVI.03340-14","article-title":"Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus","volume":"89","author":"Zaitseva","year":"2015","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1128\/AAC.00208-15","article-title":"Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection","volume":"59","author":"Berhanu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Foster, S.A., Parker, S., and Lanier, R. (2017). The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses, 9.","DOI":"10.3390\/v9110320"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2017.04.002","article-title":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits","volume":"143","author":"Grossi","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.antiviral.2014.08.003","article-title":"Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus","volume":"111","author":"Parker","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.vaccine.2019.10.049","article-title":"Co-administration of tecovirimat and ACAM2000 in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge","volume":"38","author":"Russo","year":"2020","journal-title":"Vaccine"},{"key":"ref_66","first-page":"274","article-title":"Physiologic reference ranges for captive black-tailed prairie dogs (Cynomys ludovicianus)","volume":"49","author":"Keckler","year":"2010","journal-title":"J. Am. Assoc. Lab. Anim. Sci. JAALAS"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","article-title":"A tale of two clades: Monkeypox viruses","volume":"86","author":"Likos","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4269\/ajtmh.2007.76.757","article-title":"Monkeypox zoonotic associations: Insights from laboratory evaluation of animals associated with the multi-state US outbreak","volume":"76","author":"Hutson","year":"2007","journal-title":"Am. J. Trop Med. Hyg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.virol.2010.03.012","article-title":"Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease","volume":"402","author":"Hutson","year":"2010","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jcv.2006.03.012","article-title":"Detection of monkeypox virus with real-time PCR assays","volume":"36","author":"Li","year":"2006","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1128\/JCM.42.2.601-609.2004","article-title":"Smallpox and pan-orthopox virus detection by real-time 3\u2032minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms","volume":"42","author":"Kulesh","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jviromet.2008.02.009","article-title":"A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein","volume":"150","author":"Johnson","year":"2008","journal-title":"J. Virol. Methods"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/JVI.02089-12","article-title":"Humoral immunity to smallpox vaccines and monkeypox virus challenge: Proteomic assessment and clinical correlations","volume":"87","author":"Townsend","year":"2013","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.vaccine.2011.11.021","article-title":"Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax((R)) using proteome microarrays and development of recombinant protein ELISAs","volume":"30","author":"Hermanson","year":"2012","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0506768102","article-title":"HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation","volume":"102","author":"Oseroff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/396\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:58Z","timestamp":1760176198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["vaccines8030396"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8030396","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]}}}